Prof. Arend von Stackelberg, MD

As the Chair of the world’s largest study on relapsing childhood leukemia (IntReALL), Professor von Stackelberg is the recognized leader for the treatment of relapsed and refractory in Europe. He also is faculty member at the Charité Berlin. The aim of IntReALL is to develop an optimized and internationally valid standard therapy for children with relapsed ALL. Arend von Stackelberg promotes the integration of innovative treatment for the IntReALL Study Group. IntReALL cooperates with ITCC to develop personalized treatment strategies for patients with VHR-ALL. Professor Stackelberg oversees the treatment of the most challenging patients and direct expertise with new agents and immunotherapy for acute leukemia. He is a former Chair of the IBFM Resistant Disease Committee and member of the ITCC hematology Committee. This includes testing new substances in their efficacy against VHR leukemia. As such the team lead by Arend von Stackelberg is a key partner to all ongoing efforts in VHR leukemia across Europe.